$87.835
0.875[1.01%]
Last update: 12:19PM Get Real Time Here
Edwards Lifesciences
(NYSE:EW)Edwards Lifesciences Stock (NYSE:EW), Analyst Ratings, Price Targets, Predictions
Edwards Lifesciences Corp has a consensus price target of $85, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Mizuho, and Evercore ISI Group on April 15, 2024, April 11, 2024, and April 4, 2024. With an average price target of $99.33 between RBC Capital, Mizuho, and Evercore ISI Group, there's an implied 13.27% upside for Edwards Lifesciences Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Mizuho
Evercore ISI Group
Citigroup
OTR Global
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Edwards Lifesciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 15.17% | RBC Capital | Shagun Singh | $95 → $101 | Maintains | Outperform | Get Alert |
| 04/11/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 19.73% | Mizuho | Anthony Petrone | $95 → $105 | Maintains | Buy | Get Alert |
| 04/04/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 4.9% | Evercore ISI Group | Vijay Kumar | $86 → $92 | Maintains | In-Line | Get Alert |
| 04/03/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 11.75% | Citigroup | Joanne Wuensch | $90 → $98 | Maintains | Neutral | Get Alert |
| 03/26/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | — | OTR Global | — | — | Upgrade | Mixed → Positive | Get Alert |
| 03/21/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 17.45% | Morgan Stanley | Patrick Wood | $95 → $103 | Maintains | Overweight | Get Alert |
| 03/18/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 14.03% | Oppenheimer | Suraj Kalia | $93 → $100 | Maintains | Outperform | Get Alert |
| 03/07/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | — | B of A Securities | Travis Steed | — | Upgrade | Neutral → Buy | Get Alert |
| 02/07/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | -5.36% | Stifel | Rick Wise | $70 → $83 | Maintains | Hold | Get Alert |
| 02/07/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 8.32% | Morgan Stanley | Patrick Wood | $80 → $95 | Maintains | Overweight | Get Alert |
| 02/07/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 8.32% | RBC Capital | Shagun Singh | $82 → $95 | Maintains | Outperform | Get Alert |
| 02/07/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 8.32% | Mizuho | Anthony Petrone | $85 → $95 | Maintains | Buy | Get Alert |
| 02/02/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | 7.18% | Wells Fargo | Larry Biegelsen | → $94 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 01/12/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | -6.5% | RBC Capital | Shagun Singh | $80 → $82 | Maintains | Outperform | Get Alert |
| 01/04/2024 | EW | Buy Now | Edwards Lifesciences | $87.70 | -12.2% | Evercore ISI Group | Vijay Kumar | $80 → $77 | Downgrade | Outperform → In-Line | Get Alert |
| 12/22/2023 | EW | Buy Now | Edwards Lifesciences | $87.70 | -4.22% | Truist Securities | Richard Newitter | $78 → $84 | Maintains | Buy | Get Alert |
| 12/11/2023 | EW | Buy Now | Edwards Lifesciences | $87.70 | -11.06% | Truist Securities | Richard Newitter | $76 → $78 | Maintains | Buy | Get Alert |
| 12/11/2023 | EW | Buy Now | Edwards Lifesciences | $87.70 | — | Citigroup | Joanne Wuensch | — | Downgrade | Buy → Neutral | Get Alert |
| 12/04/2023 | EW | Buy Now | Edwards Lifesciences | $87.70 | -8.78% | Morgan Stanley | Patrick Wood | $102 → $80 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Edwards Lifesciences (EW)?
The latest price target for Edwards Lifesciences (NYSE: EW) was reported by RBC Capital on April 15, 2024. The analyst firm set a price target for $101.00 expecting EW to rise to within 12 months (a possible 14.99% upside). 54 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edwards Lifesciences (EW)?
The latest analyst rating for Edwards Lifesciences (NYSE: EW) was provided by RBC Capital, and Edwards Lifesciences maintained their outperform rating.
When was the last upgrade for Edwards Lifesciences (EW)?
The last upgrade for Edwards Lifesciences Corp happened on March 26, 2024 when OTR Global raised their price target to N/A. OTR Global previously had a mixed for Edwards Lifesciences Corp.
When was the last downgrade for Edwards Lifesciences (EW)?
The last downgrade for Edwards Lifesciences Corp happened on January 4, 2024 when Evercore ISI Group changed their price target from $80 to $77 for Edwards Lifesciences Corp.
When is the next analyst rating going to be posted or updated for Edwards Lifesciences (EW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edwards Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edwards Lifesciences was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating Edwards Lifesciences (EW) correct?
While ratings are subjective and will change, the latest Edwards Lifesciences (EW) rating was a maintained with a price target of $95.00 to $101.00. The current price Edwards Lifesciences (EW) is trading at is $87.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.